BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...from Bioeconomy Capital, Casdin Capital LLC, OS Fund, Sustainable Conversion Ventures, Universal Materials Incubator and WRF Capital...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...AppTec Co. Ltd., as well as Alexandria Venture Investments, Arch Venture Partners, Watson Fund and WRF Capital...
BioCentury | Aug 31, 2018
Financial News

ApoGen expands series A to $11M

...Arch Venture Partners, Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson Innovation-JJDC Inc., Watson Fund, WRF Capital...
BioCentury | Sep 13, 2017
Emerging Company Profile

Not PGE2's first Rodeo

...Venture, Eli Lilly and Co. , Johnson & Johnson Innovation -- JJDC Inc., Watson Fund, WRF Capital...
BioCentury | Jul 28, 2017
Financial News

Accelerator leads Rodeo's series A

...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Jul 25, 2017
Financial News

Accelerator leads Rodeo's series A round

...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Mar 30, 2017
Emerging Company Profile

Resisting resistance

...Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation- JJDC, Watson Fund, WRF Capital...
BioCentury | Dec 14, 2016
Financial News

ApoGen completes venture financing

...Arch Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation-JJDC, Watson Fund, WRF Capital...
BioCentury | Dec 13, 2016
Financial News

ApoGen debuts with $7M

...NYSE:LLY), the Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Feb 15, 2016
Financial News

M3 Biotechnology completes venture financing

...Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors: WRF Capital...
Items per page:
1 - 10 of 41
BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...from Bioeconomy Capital, Casdin Capital LLC, OS Fund, Sustainable Conversion Ventures, Universal Materials Incubator and WRF Capital...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...AppTec Co. Ltd., as well as Alexandria Venture Investments, Arch Venture Partners, Watson Fund and WRF Capital...
BioCentury | Aug 31, 2018
Financial News

ApoGen expands series A to $11M

...Arch Venture Partners, Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson Innovation-JJDC Inc., Watson Fund, WRF Capital...
BioCentury | Sep 13, 2017
Emerging Company Profile

Not PGE2's first Rodeo

...Venture, Eli Lilly and Co. , Johnson & Johnson Innovation -- JJDC Inc., Watson Fund, WRF Capital...
BioCentury | Jul 28, 2017
Financial News

Accelerator leads Rodeo's series A

...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Jul 25, 2017
Financial News

Accelerator leads Rodeo's series A round

...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Mar 30, 2017
Emerging Company Profile

Resisting resistance

...Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation- JJDC, Watson Fund, WRF Capital...
BioCentury | Dec 14, 2016
Financial News

ApoGen completes venture financing

...Arch Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation-JJDC, Watson Fund, WRF Capital...
BioCentury | Dec 13, 2016
Financial News

ApoGen debuts with $7M

...NYSE:LLY), the Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital...
BioCentury | Feb 15, 2016
Financial News

M3 Biotechnology completes venture financing

...Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors: WRF Capital...
Items per page:
1 - 10 of 41